Company Overview

About VoxelMD

VoxelMD builds clinical-grade AI that reads medical images and drafts diagnostic reports.

Founded by a practicing Neuroradiologist who both treats patients and writes every line of code. Self-funded from day one.

Our Mission

To eliminate the diagnostic bottleneck in radiology by building AI that automates the tedious parts of reporting — so radiologists can focus on what matters: patient care.

Company Facts

Legal Entity
Silicon Health Solutions LLC
Founded
2025
Headquarters
United States
Team Size
1 (Sole Founder)
Stage
Pre-Seed
Compliance
HIPAA Compliant

Founder

Mo Fakhri, MD

Mo Fakhri, MD

Founder & CEO · Practicing Neuroradiologist

Practicing Neuroradiologist with deep clinical expertise in diagnostic imaging. Reads thousands of studies annually across CT, MRI, and Ultrasound modalities.

Harvard Medical School (postdoctoral research fellow), UCSF (Neuroradiology fellowship), Mallinckrodt Institute of Radiology at Washington University in St. Louis (residency).

NIH T32 Research Grant and RSNA Research Resident Grant recipient. Published research in functional brain MRI and clinical neuroimaging.

Full-stack technical founder. Writes every line of production code — from GPU-accelerated model inference to EHR integration pipelines. Proficient in Python, TypeScript, and CUDA.

HarvardUCSFMallinckrodtNIH T32RSNA GrantSelf-FundedFull-Stack Dev

Milestones

2025

Company Founded

Silicon Health Solutions LLC incorporated. Self-funded by founder.

2025

Voxel Suite Built

Radiology workflow automation tool built from scratch. EHR + PACS integration.

2025

Beta Launch

10 radiologists onboarded to active beta. 80% dictation time reduction validated.

2025

Voxel Vision Prototypes

Thyroid Ultrasound reader and CT Perfusion drafter prototypes completed.

2025

Dual Deployment Architecture

On-premise NVIDIA GPU inference pipeline and HIPAA-compliant cloud pathway (Vertex AI + BAA) both validated.

Next

Pre-Seed Raise & FDA Pathway

Seeking pre-seed investment for team expansion, clinical validation, and FDA pre-submission.

Get in Touch

Whether you're a radiologist interested in early access, an investor, or a potential partner — we'd love to hear from you.